Dexcom (DXCM) director awarded 5,575 RSUs vesting by 2027 meeting

Rhea-AI Filing Summary

AUGUSTINOS NICHOLAS reported acquisition or exercise transactions in this Form 4 filing.

Dexcom Inc. director Nicholas Augustinos reported a new equity award and updated holdings. He received a grant of 5,575 restricted stock units (RSUs) on May 28, 2026, with each RSU representing one share of Dexcom common stock upon settlement.

The RSUs will vest 100% on the earlier of the one-year anniversary of the grant date or Dexcom's 2027 Annual Meeting of Stockholders. Following this award, he holds 5,575 shares directly and 38,457 shares indirectly through the Kirschner/Augustinos Revocable Trust, where he serves as a trustee.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider AUGUSTINOS NICHOLAS

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,575	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 5,575 shares (Direct, null); Common Stock — 38,457 shares (Indirect, by Trust)

Footnotes (1)

1. The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement. Shares are held by the Kirschner/Augustinos Revocable Trust, with respect to which the Reporting Person is a trustee.

Key Figures

RSU grant size: 5,575 RSUs RSU vesting schedule: 100% cliff vest Direct holdings after grant: 5,575 shares +2 more

5 metrics

RSU grant size 5,575 RSUs Granted May 28, 2026 to director Nicholas Augustinos

RSU vesting schedule 100% cliff vest Earlier of one year from May 28, 2026 or 2027 Annual Meeting

Direct holdings after grant 5,575 shares Dexcom common stock held directly following RSU award

Indirect trust holdings 38,457 shares Dexcom common stock held by Kirschner/Augustinos Revocable Trust

RSU grant price $0.00 per share Stock-based compensation award, no cash purchase price

Key Terms

restricted stock unit (RSU), Annual Meeting of Stockholders, Revocable Trust

3 terms

restricted stock unit (RSU) financial

"Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share"

A restricted stock unit (RSU) is a promise from a company to give an employee company shares (or cash equal to their value) at a future date if certain conditions are met, such as staying with the company or hitting performance targets. For investors, RSUs matter because when they convert into actual shares they increase the number of shares available and can create selling pressure as employees cash out—think of them as a future paycheck paid in company stock.

Annual Meeting of Stockholders regulatory

"will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders"

Revocable Trust financial

"Shares are held by the Kirschner/Augustinos Revocable Trust, with respect to which the Reporting Person is a trustee"

A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

AUGUSTINOS NICHOLAS

(Last) (First) (Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/28/2026		A		5,575(1)	A	$0	5,575	D
Common Stock								38,457	I	by Trust(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

2. Shares are held by the Kirschner/Augustinos Revocable Trust, with respect to which the Reporting Person is a trustee.

Remarks:

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Nicholas Augustinos	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Dexcom (DXCM) director Nicholas Augustinos report?

Nicholas Augustinos reported receiving a grant of 5,575 RSUs. The award was made on May 28, 2026, and each restricted stock unit represents a contingent right to receive one share of Dexcom common stock upon settlement, reflecting stock-based compensation rather than an open-market purchase.

How do the new RSUs granted to Dexcom (DXCM) director vest?

The 5,575 RSUs vest in a single tranche. They will vest 100% on the earlier of the one-year anniversary of the May 28, 2026 grant date or the date of Dexcom’s 2027 Annual Meeting of Stockholders, tying vesting to board service and the shareholder meeting schedule.

How many Dexcom (DXCM) shares does Nicholas Augustinos hold after this Form 4?

After this filing, Nicholas Augustinos holds shares both directly and indirectly. He reports 5,575 Dexcom common shares directly from the RSU award and 38,457 shares held indirectly through the Kirschner/Augustinos Revocable Trust, where he is a trustee, consolidating his reported equity exposure.

What is the role of the Kirschner/Augustinos Revocable Trust in Dexcom (DXCM) holdings?

The Kirschner/Augustinos Revocable Trust holds Dexcom shares for the reporting person. The Form 4 notes that 38,457 Dexcom common shares are held by this revocable trust, with Nicholas Augustinos serving as a trustee, indicating indirect ownership of those shares through the trust structure.

Did Dexcom (DXCM) director Nicholas Augustinos buy or sell shares for cash in this Form 4?

No open-market buy or sell is reported in this Form 4. The filing shows a stock-based compensation grant of 5,575 RSUs at a stated price per share of $0.00 and an updated indirect holding via a revocable trust, without any cash purchase or sale transaction.